by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | May 19, 2025 | Blog
FDA Roadmap to Reducing Animal Testing:A Step Toward Smarter Tools for in silico Immunogenicity Risk Assessment The FDA’s new Roadmap to Reducing Animal Testing in Preclinical Safety Studies lays out a phased plan to move away from animal models and toward...
by Elena Iemma | Apr 30, 2025 | Blog
Is “Artificial” Intelligence an Option for your ADA? In Case You Missed It: Better ADA Prediction! Guilhem Richard, our CTO, recently presented our new ADA (anti-drug antibody) prediction model to the Antibody Society. The accuracy of the model improved...
